Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...

Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically ...

The Family Health Care Institute bulletin (one of King Hussein Foundation's institutes), on this Sunday, discusses nasal and ...

Dupixent sBLA accepted for priority review by the US FDA with a target action date of February 28, 2026; if approved, Dupixent would be the first and only medicine indicated specifically for AFRS, ...

Cold air, dust and autumn walks can turn a harmless atchoo into a nagging puzzle for worried dog owners. A quick sneeze now ...

Clinicians have a new line of weapons in their arsenal to treat recurring nasal polyps. Over the past year several new monoclonal antibody-based biologic drugs have been approved to treat the ...

Implementing endoscopy requires a significant investment in a dedicated suite, special equipment (light sources, video ...